We tested the efficacy of WEHI-7326 in two PDX models of relapsed or refractory high-risk neuroblastoma with MYCN amplification28, and in a Th-MYCN transgenic mouse model of high-risk neuroblastoma29. The gene discussed is MYCN; the disease is neuroblastoma.